-
1
-
-
84862777035
-
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
-
COI: 1:CAS:528:DC%2BC38Xps1Kiu7g%3D, PID: 22315472
-
Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673–84.
-
(2012)
Gut
, vol.61
, Issue.5
, pp. 673-684
-
-
Deng, N.1
Goh, L.K.2
Wang, H.3
Das, K.4
Tao, J.5
Tan, I.B.6
-
2
-
-
84918815964
-
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
-
COI: 1:CAS:528:DC%2BC2cXitVyktbzI, PID: 25220842
-
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
-
(2015)
Int J Cancer
, vol.136
, Issue.5
, pp. E359-E386
-
-
Ferlay, J.1
Soerjomataram, I.2
Dikshit, R.3
Eser, S.4
Mathers, C.5
Rebelo, M.6
-
3
-
-
84917709107
-
Apatinib for the treatment of gastric cancer
-
COI: 1:CAS:528:DC%2BC2cXitV2ntr3I
-
Geng R, Li J. Apatinib for the treatment of gastric cancer. Expert Opin Pharmaco. 2015;16(1):117–22.
-
(2015)
Expert Opin Pharmaco
, vol.16
, Issue.1
, pp. 117-122
-
-
Geng, R.1
Li, J.2
-
4
-
-
84891371156
-
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
-
COI: 1:CAS:528:DC%2BC3sXitVWjurjL, PID: 24332238
-
Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78–86.
-
(2014)
Lancet Oncol
, vol.15
, Issue.1
, pp. 78-86
-
-
Ford, H.E.1
Marshall, A.2
Bridgewater, J.A.3
Janowitz, T.4
Coxon, F.Y.5
Wadsley, J.6
-
5
-
-
84944472832
-
Molecular classification of gastric cancer: towards a pathway-driven targeted therapy
-
Riquelme I, Saavedra K, Espinoza JA, Weber H, Garcia P, Nervi B, et al. Molecular classification of gastric cancer: towards a pathway-driven targeted therapy. Oncotarget. 2015;28(6):24750–79.
-
(2015)
Oncotarget
, vol.28
, Issue.6
, pp. 24750-24779
-
-
Riquelme, I.1
Saavedra, K.2
Espinoza, J.A.3
Weber, H.4
Garcia, P.5
Nervi, B.6
-
6
-
-
84893000964
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport
-
COI: 1:CAS:528:DC%2BC2cXlt1Wkur4%3D
-
Shen L, Xu JM, Feng FY, Jiao SC, Wang LW, Li J, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport. Chinese J Oncol. 2013;35(4):295–300.
-
(2013)
Chinese J Oncol
, vol.35
, Issue.4
, pp. 295-300
-
-
Shen, L.1
Xu, J.M.2
Feng, F.Y.3
Jiao, S.C.4
Wang, L.W.5
Li, J.6
-
7
-
-
84891041748
-
Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era
-
Shah MA. Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era. Nat Rev Clin Oncol. 2014;11(1):10–1.
-
(2014)
Nat Rev Clin Oncol
, vol.11
, Issue.1
, pp. 10-11
-
-
Shah, M.A.1
-
8
-
-
84928295481
-
Targeted therapy in gastric cancer
-
COI: 1:CAS:528:DC%2BC2MXhtVOiurvN, PID: 25706252
-
Thiel A, Ristimaki A. Targeted therapy in gastric cancer. APMIS. 2015;123(5):365–72.
-
(2015)
APMIS
, vol.123
, Issue.5
, pp. 365-372
-
-
Thiel, A.1
Ristimaki, A.2
-
9
-
-
84938097560
-
Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells
-
PID: 26201693
-
Raha S, Yumnam S, Hong GE, Lee HJ, Saralamma VV, Park HS, et al. Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells. Int J Oncol. 2015;47(3):1061–9.
-
(2015)
Int J Oncol
, vol.47
, Issue.3
, pp. 1061-1069
-
-
Raha, S.1
Yumnam, S.2
Hong, G.E.3
Lee, H.J.4
Saralamma, V.V.5
Park, H.S.6
-
10
-
-
77954235111
-
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response
-
COI: 1:CAS:528:DC%2BC3cXot1Wlsbw%3D, PID: 20472680
-
Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res. 2010;16(13):3329–34.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.13
, pp. 3329-3334
-
-
Pratilas, C.A.1
Solit, D.B.2
-
11
-
-
68249093818
-
Targeting the phosphoinositide 3-kinase pathway in cancer
-
COI: 1:CAS:528:DC%2BD1MXpt1Wgtb4%3D, PID: 19644473
-
Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–44.
-
(2009)
Nat Rev Drug Discov
, vol.8
, Issue.8
, pp. 627-644
-
-
Liu, P.1
Cheng, H.2
Roberts, T.M.3
Zhao, J.J.4
-
12
-
-
84894546548
-
Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome
-
PID: 24587678
-
Lim SM, Lim JY, Cho JY. Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome. World J Gastroenterol. 2014;20(8):2042–50.
-
(2014)
World J Gastroenterol
, vol.20
, Issue.8
, pp. 2042-2050
-
-
Lim, S.M.1
Lim, J.Y.2
Cho, J.Y.3
-
13
-
-
84869790015
-
Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma
-
COI: 1:CAS:528:DC%2BC38XhslyisLfM, PID: 23155330
-
Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol. 2012;18(42):6005–17.
-
(2012)
World J Gastroenterol
, vol.18
, Issue.42
, pp. 6005-6017
-
-
Kudo, M.1
-
14
-
-
55749088393
-
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
-
COI: 1:CAS:528:DC%2BD1cXht1ensLfE, PID: 18852116
-
Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129–40.
-
(2008)
Mol Cancer Ther
, vol.7
, Issue.10
, pp. 3129-3140
-
-
Wilhelm, S.M.1
Adnane, L.2
Newell, P.3
Villanueva, A.4
Llovet, J.M.5
Lynch, M.6
-
15
-
-
4944249117
-
BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
COI: 1:CAS:528:DC%2BD2cXotFalsbk%3D, PID: 15466206
-
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–109.
-
(2004)
Cancer Res
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
-
16
-
-
23044510046
-
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors
-
COI: 1:CAS:528:DC%2BD2MXmvFSmtbY%3D, PID: 16061863
-
Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11(15):5472–80.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.15
, pp. 5472-5480
-
-
Clark, J.W.1
Eder, J.P.2
Ryan, D.3
Lathia, C.4
Lenz, H.J.5
-
17
-
-
77954574658
-
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203
-
COI: 1:CAS:528:DC%2BC3cXptlajtb4%3D, PID: 20458043
-
Sun W, Powell M, O’Dwyer PJ, Catalano P, Ansari RH, Benson III AB. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28(18):2947–51.
-
(2010)
J Clin Oncol
, vol.28
, Issue.18
, pp. 2947-2951
-
-
Sun, W.1
Powell, M.2
O’Dwyer, P.J.3
Catalano, P.4
Ansari, R.H.5
Benson, A.B.6
-
18
-
-
84924175796
-
Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma
-
PID: 25499255
-
Du R, Wu S, Lv X, Fang H, Wu S, Kang J. Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. J Exp Clin Cancer Res. 2014;33:105.
-
(2014)
J Exp Clin Cancer Res
, vol.33
, pp. 105
-
-
Du, R.1
Wu, S.2
Lv, X.3
Fang, H.4
Wu, S.5
Kang, J.6
-
19
-
-
84898016402
-
Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells
-
COI: 1:CAS:528:DC%2BC3sXlvVCmtrg%3D, PID: 23584483
-
Wu MH, Huang CY, Lin JA, Wang SW, Peng CY, Cheng HC, et al. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene. 2014;33(13):1725–35.
-
(2014)
Oncogene
, vol.33
, Issue.13
, pp. 1725-1735
-
-
Wu, M.H.1
Huang, C.Y.2
Lin, J.A.3
Wang, S.W.4
Peng, C.Y.5
Cheng, H.C.6
-
20
-
-
33744984843
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
-
COI: 1:CAS:528:DC%2BD28XmtVOmtrk%3D, PID: 16636341
-
Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505–12.
-
(2006)
J Clin Oncol
, vol.24
, Issue.16
, pp. 2505-2512
-
-
Ratain, M.J.1
Eisen, T.2
Stadler, W.M.3
Flaherty, K.T.4
Kaye, S.B.5
Rosner, G.L.6
-
21
-
-
51249090123
-
The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells
-
COI: 1:CAS:528:DC%2BD1cXhtFaisb7E, PID: 18562239
-
Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 2008;40(12):2707–19.
-
(2008)
Int J Biochem Cell Biol
, vol.40
, Issue.12
, pp. 2707-2719
-
-
Ramos, J.W.1
-
22
-
-
34547209343
-
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
-
COI: 1:CAS:528:DC%2BD2sXosFyksbk%3D, PID: 17126425
-
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.
-
(2007)
Biochim Biophys Acta
, vol.1773
, Issue.8
, pp. 1263-1284
-
-
McCubrey, J.A.1
Steelman, L.S.2
Chappell, W.H.3
Abrams, S.L.4
Wong, E.W.5
Chang, F.6
-
23
-
-
84922223454
-
Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer
-
PID: 24465527
-
Lin Z, Zhang C, Zhang M, Xu D, Fang Y, Zhou Z, et al. Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer. PLoS One. 2014;9(1), e85296.
-
(2014)
PLoS One
, vol.9
, Issue.1
-
-
Lin, Z.1
Zhang, C.2
Zhang, M.3
Xu, D.4
Fang, Y.5
Zhou, Z.6
-
24
-
-
84876249574
-
MEK and the inhibitors: from bench to bedside
-
COI: 1:CAS:528:DC%2BC3sXmvFejurg%3D, PID: 23587417
-
Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:27.
-
(2013)
J Hematol Oncol
, vol.6
, pp. 27
-
-
Akinleye, A.1
Furqan, M.2
Mukhi, N.3
Ravella, P.4
Liu, D.5
-
25
-
-
84871491627
-
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
-
PID: 23085539
-
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012;3(10):1068–111.
-
(2012)
Oncotarget
, vol.3
, Issue.10
, pp. 1068-1111
-
-
McCubrey, J.A.1
Steelman, L.S.2
Chappell, W.H.3
Abrams, S.L.4
Franklin, R.A.5
Montalto, G.6
-
26
-
-
43949116902
-
Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines
-
COI: 1:CAS:528:DC%2BD1cXmtlWhsLg%3D, PID: 18378393
-
Kim JH, Go HY, Jin DH, Kim HP, Hong MH, Chung WY, et al. Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. Cancer Lett. 2008;265(2):197–205.
-
(2008)
Cancer Lett
, vol.265
, Issue.2
, pp. 197-205
-
-
Kim, J.H.1
Go, H.Y.2
Jin, D.H.3
Kim, H.P.4
Hong, M.H.5
Chung, W.Y.6
-
27
-
-
84858984798
-
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
-
COI: 1:CAS:528:DC%2BC38XksFWmt70%3D, PID: 22443084
-
De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16 Suppl 2:S17–27.
-
(2012)
Expert Opin Ther Targets
, vol.16
, pp. S17-S27
-
-
De Luca, A.1
Maiello, M.R.2
D’Alessio, A.3
Pergameno, M.4
Normanno, N.5
-
28
-
-
27744565979
-
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
-
PID: 16255777
-
Molhoek KR, Brautigan DL, Slingluff Jr CL. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med. 2005;3:39.
-
(2005)
J Transl Med
, vol.3
, pp. 39
-
-
Molhoek, K.R.1
Brautigan, D.L.2
Slingluff, C.L.3
-
29
-
-
84904318936
-
Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
-
COI: 1:CAS:528:DC%2BC2cXntFOksbY%3D, PID: 24770582
-
Fu QH, Zhang Q, Bai XL, Hu QD, Su W, Chen YW, et al. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(8):1429–40.
-
(2014)
J Cancer Res Clin Oncol
, vol.140
, Issue.8
, pp. 1429-1440
-
-
Fu, Q.H.1
Zhang, Q.2
Bai, X.L.3
Hu, Q.D.4
Su, W.5
Chen, Y.W.6
-
30
-
-
84875238392
-
Molecular targeted agents for gastric cancer: a step forward towards personalized therapy
-
Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T. Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel). 2013;5(1):64–91.
-
(2013)
Cancers (Basel)
, vol.5
, Issue.1
, pp. 64-91
-
-
Cidon, E.U.1
Ellis, S.G.2
Inam, Y.3
Adeleke, S.4
Zarif, S.5
Geldart, T.6
-
31
-
-
0034681392
-
Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation
-
COI: 1:CAS:528:DC%2BD3cXhsVymtrw%3D, PID: 10671553
-
Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, et al. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem. 2000;275(7):5096–103.
-
(2000)
J Biol Chem
, vol.275
, Issue.7
, pp. 5096-5103
-
-
Wu, L.W.1
Mayo, L.D.2
Dunbar, J.D.3
Kessler, K.M.4
Baerwald, M.R.5
Jaffe, E.A.6
-
32
-
-
0037188941
-
Role of Akt signaling in vascular homeostasis and angiogenesis
-
COI: 1:CAS:528:DC%2BD38XltVOqur8%3D, PID: 12089061
-
Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90(12):1243–50.
-
(2002)
Circ Res
, vol.90
, Issue.12
, pp. 1243-1250
-
-
Shiojima, I.1
Walsh, K.2
|